1. 33PCombination of mTOR inhibition and paclitaxel as a personalised strategy in the context of MYC-amplified high-grade serous ovarian cancer. (7th November 2019) Authors: Martins, F C; Couturier, D-L; de Santiago, I; Vias, M; Sanders, D; Piskorz, A; Hall, J; Jimenez-Linan, M; Hosking, K; Crawford, R; Brenton, J Journal: Annals of oncology Issue: Volume 30(2019)Supplement 7 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P112 Activation of PIK3CA in a model of endometriosis may shed light on the pathogenesis of ovarian clear cell adenocarcinoma. (1st November 2019) Authors: Barbara, CF; King, C; Jimenez-Linan, M; Brenton, J; Charnock-Jones, DS Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A127 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗